Plus Therapeutics, Inc. presented updated data on December 17, 2024, from its ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda. The presentation at the 2024 San Antonio Breast Cancer Symposium focused specifically on breast cancer patients with leptomeningeal disease (LM).
The data showed that a single intrathecal dose of Rhenium (186Re) Obisbemeda delivered favorable responses. These responses were observed in cerebrospinal fluid circulating tumor cell count, imaging, and clinical evaluation.
Based on these promising results, the company intends to move forward rapidly into a breast cancer-focused expansion cohort. Both single-dose and multiple-dose expansion trials are planned for 2025 to further evaluate the therapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.